[1] Han Y, Yuan K, Zheng Y, et al. Orexin receptor antagonists as emerging treatments for psychiatric disorders[J]. Neurosci Bull, 2020, 36: 432–448.
[2] Roch C, Bergamini G, Steiner MA, et al. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia[J]. Psychopharmacology (Berl), 2021, 238: 2693–2708.
[3] De Boer P, Drevets WC, Rofael H, et al. A randomized phase 2 study to evaluate the orexin-2 receptor antagonist selt orexant in individuals with insomnia without psychiatric comorbidity[J]. J Psychopharmacol, 2018, 32: 668–677.
[4] 赵琳, 丁敏, 贾鲲鹏,等. 腹腔注射2-DG对大鼠下丘脑orexin-A神经元表达的影响[J]. 中国应用生理学杂志. 2017, 33: 500–502.
[5] Jacobson LH, Chen S, Mir S, et al. Orexin OX₂ receptor antagonists as sleep aids[J]. Current Top Behav Neurosci, 2017, 33: 105–136.
[6] Yukitake H, Fujimoto T, Ishikawa T, et al. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice[J]. Pharmacol Biochem Behav. 2019, 187: 172–194.
[7] Summers CH, Yaeger JDW, Staton CD, et al. Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: potential for therapy[J]. Brain Res. 2020, 3: 146–185.
[8] Skrzypski M, Le TT, Kaczmarek P, et al. Orexin A stimulates glucose uptake, lipid accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes[J]. Diabetologia. 2011, 54: 1841–1852